Contact Information
Research Team
NamePositionOfficePhoneEmail
Eun Ju YANGResearch Assistant (Lab Representative)N22-2027+853 8822 4217ejyang@um.edu.mo
Junfang LYUUM Macao Post-doctoral FellowN22-2027+853 8822 4217junfanglyu@um.edu.mo
Changxiang SHIPhD StudentN22-2027+853 8822 4217yb77614@um.edu.mo
Ann Pui Kei MOUPhD StudentN22-2027+853 8822 4217yb87606@um.edu.mo
Guowen RENPhD StudentN22-2027+853 8822 4217yb97622@um.edu.mo
Education
PhDDept. Bioscience & Biotechnology, Sejong University, Korea (2000-2004)
MSDept. Applied Biology, Dongguk University, Korea (1998-2000)
BSDept. Biology, Dongguk University, Korea (1990-1998)
Positions
2019-presentAssociate Professor, Faculty of Health Sciences, University of Macau
2013-2019Assistant Professor, Faculty of Health Sciences, University of Macau
2011-2013Research Associate, Dept. Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
2006-2011Postdoctoral Fellow, Dept. Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
2005-2006Research Scientist, Biotechnology Industrialization Institute, Yonsei University, Seoul, Korea
2004-2005Lecturer, Dept. Bioscience & Biotechnology, Sejong University, Seoul, Korea
2000-2001Research Assistant, Dept. Bioscience & Biotechnology, Sejong University, Seoul, Korea
Research Interests
[Exploiting synthetic lethality for cancer precision medicine]Synthetic lethality is a genetic interaction where a single gene deficiency is tolerable for cell viability while the combination of deficiencies in two genes leads to cell death. The concept of the synthetic lethality has been widely exploited in cancer research field because a large portion of cancer has loss-of-function mutations in tumor suppressor genes. Synthetic lethality utilizes the mutations in tumor suppressor genes as a mark for selectivity of anticancer drugs. Pharmacological or genetic perturbation of a synthetic lethality partner of a tumor suppressor will cause selective lethality of the cancer cells that carry the tumor suppressor mutation. As it provides a strong cancer cell selectivity, synthetic lethality is one of core approaches for cancer precision medicine.

 

My lab is studying major tumor suppressor genes, including p53, PTEN, RB1, BRCA1, ARID1A, and SMAD4, and is expanding to newly identified tumor suppressors. We have established isogenic cell pairs for the tumor suppressor genes and actively working on identifying synthetic lethality partners using chemical and genetic screenings.

Representative Publications
  1. Zhang, B. Y., Lyu, J. F., Yang, E. J., Liu, Y. F., Wu, C. J., Pardeshi, L., Tan, K. L., Chen, Q., Xu, X. L., Deng, C. X., and Shim, J. S. (2020) Class I Histone Deacetylase Inhibition Is Synthetic Lethal with BRCA1 Deficiency in Breast Cancer Cells. Acta Pharm Sin B 10, 615-627
  2. Liu, Y. F., Yang, E. J., Shi, C. X., Mou, P. K., Zhang, B. Y., Wu, C. J., Lyu, J. F., and Shim, J. S. (2020) Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT. Int J Biol Sci 16, 1774-1784
  3. Lyu, J. F., Yang, E. J., and Shim, J. S. (2019) Cholesterol Trafficking: An Emerging Therapeutic Target for Angiogenesis and Cancer. Cells 8, E389
  4. Zhang, B. Y., Lyu, J. F., Liu, Y. F., Wu, C. J., Yang, E. J., Pardeshi, L., Tan, K., Wong, K. H., Chen, Q., Xu, X. l., Deng, C. X., and Shim, J. S. (2018) BRCA1 Deficiency Sensitizes Breast Cancer Cells to Bromodomain and Extra-Terminal Domain (BET) Inhibition. Oncogene 37, 6341-6356
  5. Wu, C. J., Lyu, J. F., Yang, E. J., Liu, Y. F., Zhang, B. Y., and Shim, J. S. (2018) Targeting AURKA-CDC25C Axis to Induce Synthetic Lethality in ARID1A-Deficient Colorectal Cancer Cells. Nat Commun 9, 3212
  6. Lyu, J. F., Yang, E. J., Head, S., Ai, N., Zhang, B. Y., Wu, C. J., Li, R. J., Liu, Y. F., Chakravarty, H., Zhang, S. L., Tam, K. Y., Dang, Y. J., Kwon, H. J., Ge, W., Liu, J. O., and Shim, J. S. (2018) Astemizole Inhibits mTOR Signaling and Angiogenesis by Blocking Cholesterol Trafficking. Int J Biol Sci 14, 1175-1185
  7. Liu, Y., Yang, E. J., Zhang, B. Y., Miao, Z. Q., Wu, C. J., Lyu, J. F., Tan, K., Poon, T. C. W., and Shim, J. S. (2018) PTEN Deficiency Confers Colorectal Cancer Cell Resistance to Dual Inhibitors of FLT3 and Aurora kinase A. Cancer Lett 436, 28-37
  8. Lyu, J. F., Yang, E. J., Head, S., Ai, N., Zhang, B. Y., Wu, C. J., Li, R. J., Liu, Y. F., Yang, C., Dang, Y. J., Kwon, H. J., Ge, W., Liu, J. O., and Shim, J. S. (2017) Pharmacological Blockade of Cholesterol Trafficking by Cepharanthine in Endothelial Cells Suppresses Angiogenesis and Tumor Growth. Cancer Lett 409, 91-103
  9. Head, S., Shi, W., Yang, E. J., Nacev, B., Hong, S., Pasunooti, K., Li, R. J., Shim, J. S., and Liu, J. O. (2017) Simultaneous Targeting of Npc1 and Vdac1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. Acs Chem Biol 12, 174-182
  10. Shim, J. S., Li, R. J., Bumpus, N., Head, S., Pasunooti, K. K., Yang, E. J., Lv, J. f., Shi, W., and Liu, J. O. (2016) Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole. Clin Cancer Res 22, 2709-2720
  11. Du, B. W., and Shim, J. S. (2016) Targeting Epithelial–Mesenchymal Transition (Emt) to Overcome Drug Resistance in Cancer. Molecules 21, 965
  12. Cho, Y. S., Yen, C. n., Shim, J. S., Kang, D. H., Kang, S. W., Liu, J. O., and Kwon, H. J. (2016) Antidepressant Indatraline Induces Autophagy and Inhibits Restenosis Via Suppression of mTOR/S6 Kinase Signaling Pathway. Sci Rep-Uk 6, 34655
  13. Wang, G. L., Rajpurohit, S., Delaspre, F., Walker, S., White, D., Ceasrine, A., Kuruvilla, R., Li, R. j., Shim, J. S., Liu, J. O., Parsons, M., and Mumm, J. (2015) First Quantitative High-Throughput Screen in Zebrafish Identifies Novel Pathways for Increasing Pancreatic Β-Cell Mass. Elife 4, e08261
  14. Shim, J. S., Li, R. J., Lv, J. F., Head, S., Yang, E. J., and Liu, J. O. (2015) Inhibition of Angiogenesis by Selective Estrogen Receptor Modulators through Blockade of Cholesterol Trafficking Rather Than Estrogen Receptor Antagonism. Cancer Lett 362, 106-115
  15. Head, S. A., Shi, W., Zhao, L., Gorshkov, K., Pasunooti, K., Chen, Y., Deng, Z., Li, R. j., Shim, J. S., Tan, W., Hartung, T., Zhang, J., Zhao, Y., Colombini, M., and Liu, J. O. (2015) Antifungal Drug Itraconazole Targets Vdac1 to Modulate the Ampk/mTOR Signaling Axis in Endothelial Cells. Proceedings of the National Academy of Sciences 112, E7276-E7285
  16. Wang, M. H., Shim, J. S., Li, R. J., Dang, Y. J., He, Q. L., Das, M., and Liu, J. O. (2014) Identification of an Old Antibiotic Clofoctol as a Novel Activator of Unfolded Protein Response Pathways and an Inhibitor of Prostate Cancer. Brit J Pharmacol 171, 4478-4489
  17. Shim, J. S., and Liu, J. O. (2014) Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs. Int J Biol Sci 10, 654-663
  18. Kamiyama, H., Rauenzahn, S., Shim, J. S., Karikari, C. A., Feldmann, G., Hua, L., Kamiyama, M., Schuler, F. W., Lin, M. T., Beaty, R. M., Karanam, B., Liang, H., Mullendore, M. E., Mo, G., Hidalgo, M., Jaffee, E., Hruban, R. H., Jinnah, H. A., Roden, R. B., Jimeno, A., Liu, J. O., Maitra, A., and Eshleman, J. R. (2013) Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. Clin Cancer Res 19, 1139-1146
  19. Choi, S. M., Kim, Y., Shim, J. S., Park, J. T., Wang, R. H., Leach, S. D., Liu, J. O., Deng, C., Ye, Z., and Jang, Y. Y. (2013) Efficient Drug Screening and Gene Correction for Treating Liver Disease Using Patient-Specific Stem Cells. Hepatology 57, 2458-2468
  20. Shim, J. S., Rao, R., Beebe, K., Neckers, L., Han, I., Nahta, R., and Liu, J. O. (2012) Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir. J Natl Cancer Inst 104, 1576-1590
  21. Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S. J., Anders, R. A., Liu, J. O., and Pan, D. (2012) Genetic and Pharmacological Disruption of the TEAD-YAP Complex Suppresses the Oncogenic Activity of YAP. Genes Dev 26, 1300-1305
  22. Rovira, M., Huang, W., Yusuff, S., Shim, J. S., Ferrante, A. A., Liu, J. O., and Parsons, M. J. (2011) Chemical Screen Identifies FDA-Approved Drugs and Target Pathways That Induce Precocious Pancreatic Endocrine Differentiation. Proc Natl Acad Sci U S A 108, 19264-19269
  23. Platz, E. A., Yegnasubramanian, S., Liu, J. O., Chong, C. R., Shim, J. S., Kenfield, S. A., Stampfer, M. J., Willett, W. C., Giovannucci, E., and Nelson, W. G. (2011) A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment. Cancer Discov 1, 68-77
  24. Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H. E., Dhara, S., Han, K. C., Chong, C. R., Pomper, M. G., So, A., and Liu, J. O. (2010) Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer. J Natl Cancer Inst 102, 1855-1873
  25. Shim, J. S., Lee, H. K., Park, H. M., Kim, J. O., Kim, E. K., Hwang, K. H., Kim, K. T., Park, S. W., Lee, J. H., and Kwon, H. J. (2005) Development of Anangiogenesis-Focused cDNA Chip and Validation of Its Functionality. Exp Mol Med 37, 365-370
  26. Shim, J. S., Lee, J., Park, H. J., Park, S. J., and Kwon, H. J. (2004) A New Curcumin Derivative, HBC, Interferes with the Cell Cycle Progression of Colon Cancer Cells Via Antagonization of the Ca2+/Calmodulin Function. Chem Biol 11, 1455-1463
  27. Shim, J. S., Lee, H. S., Shin, J., and Kwon, H. J. (2004) Psammaplin A, a Marine Natural Product, Inhibits Aminopeptidase N and Suppresses Angiogenesis in Vitro. Cancer Lett 203, 163-169
  28. Shim, J. S., and Kwon, H. J. (2004) Chemical Genetics for Therapeutic Target Mining. Expert Opin Ther Targets 8, 653-661
  29. Shim, J. S., Kim, D. H., and Kwon, H. J. (2004) Plakoglobin Is a New Target Gene of Histone Deacetylase in Human Fibrosarcoma HT1080 Cells. Oncogene 23, 1704-1711
  30. Shim, J. S., Kim, J. H., Cho, H. Y., Yum, Y. N., Kim, S. H., Park, H. J., Shim, B. S., Choi, S. H., and Kwon, H. J. (2003) Irreversible Inhibition of CD13/aminopeptidase N by the Antiangiogenic Agent Curcumin. Chem Biol 10, 695-704
Research Grants
  1. Macau Science and Technology Development Fund (FDCT-0030-2020-A): (2020-2021) Drug repurposing approach for the rapid discovery of therapeutics for SARS-CoV-2 infection. Total Budget: MOP 400,000
  2. UM Multi-Year Research Grant (MYRG2019-00116-FHS): (2020-2022) Therapeutic targeting of RB1 tumor suppressor mutation in lung cancer cells by aurora kinase A inhibition. Total budget: MOP 450,000
  3. UM Multi-Year Research Grant (MYRG2017-00176-FHS): (2017-2020) Targeted inhibition of ARID1A-deficient colorectal cancer cells by synthetic lethality. Total budget: MOP 898,800
  4. Macau Science and Technology Development Fund (FDCT-024-2015-A1): (2015-2018) Development of drugs targeting mitochondria to inhibit castration-resistant prostate cancer. Total Budget: MOP 1,470,000
  5. UM Multi-Year Research Grant (MYRG2015-00181-FHS): (2015-2018) Discovery of synthetic lethal microRNA to the tumor suppressor PTEN and its application for targeted cancer therapy. Total budget: MOP 1,569,600
  6. UM Matching Research Grant (MRG002-JSS-2015-FHS): (2014-2017) Discovery of novel anti-angiogenic and anticancer agents from a clinical drug library. Total budget: MOP 559,000
  7. Macau Science and Technology Development Fund (FDCT-119-2013-A3): (2014-2017) Discovery of novel anti-angiogenic and anticancer agents from a clinical drug library. Total budget: MOP 1,679,000
  8. UM Startup Research Grant (SRG2013-00045-FHS): (2013-2015) A novel mechanism of angiogenesis inhibition by tamoxifen. Total budget: MOP 100,000
Patents
International patent: WO/2010/042163 – Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders. Liu JO, Shim JS, Chong CR, and Bhat S. 04/15/2010
Korea patent: 1006410760000 – A novel aminopeptidase N Inhibitor. Kwon HJ, Lee J and Shim JS. 10/25/2006
Korea patent: 1006046970000 – A novel calmodulin antagonist and an immunosuppressive agent comprising thereof. Kwon HJ, Shim JS and Lee J. 07/19/2006
International patent: WO/2003/105751 – Novel curcumin derivatives. Kwon HJ, Shim JS, Kim JH, Choi SH, Shin JH and Rho JR. 12/24/2003
Awards 
06/25/2011Young Investigator Award in “2011 KSEA/KASBP Northeast Regional Conference and Bio Fair”, Edison, NJ, USA
05/25/2004Best Poster Award in “The 61st Annual Meeting 2004” of the Korean Society for Biochemistry and Molecular Biology, Seoul, Korea
10/18/2001Best Poster Award in “The Annual Meeting 2001” of the Korean Society for Biochemistry and Molecular Biology, Seoul, Korea
Professional Activities
2019-presentEditorial Board Member of Molecular Medicine Reports (Spandidos Publication)
2013-presentMember of the Korean Society for Biochemistry and Molecular Biology (KSBMB)
2010-2019Member of the American Chemical Society (ACS)
2015-2018Member of the Society for Laboratory Automation and Screening (SLAS)
2011-2013Member of the Korean-American Scientists and Engineers Association (KSEA)
2011-2013Member of the Korean-American Professional Community in Biotechnology and Pharmaceuticals (KASBP)
2011-2012Vice President of the Baltimore Life Scientist Association (BLSA)